AZN astrazeneca.com: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

AstraZeneca Plc - graphic logo of issuer AZN

AstraZeneca PLC (AZN) relies on patent protection for critical medications, allowing the company to independently determine therapy costs. The EV/EBITDA multiple for AstraZeneca PLC (AZN) on the GURU.Markets daily chart confirms this trend, where 15.28 represents the latest metric reading. Business resilience is based on a biopharmaceutical ecosystem in oncology, while colossal clinical trial costs create an insurmountable barrier to entry.

AstraZeneca Plc - AZN Enterprise Value to Operating Income Before Depreciation (period 11/23/2025 - 11/10/2026)

astrazeneca.com - analytical breakdowns and key metrics (AZN)

- market price and analyst price targets:
Price Chart AstraZeneca AB|AZN - Average Forecast Price
- company stock capitalization data:
Market Value AstraZeneca Corp.|AZN - Total Company Value
- book value of equity indicators:
Book Value per Share AstraZeneca|AZN - Accounting Capitalization|Market Capitalization to Book Value Ratio astrazeneca.com|AZN - Company Total Asset Base
- business debt structure and liquidity details:
Debt to Equity AstraZeneca PLC|AZN - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital AstraZeneca|AZN - Company Total Indebtedness|Debts to Book Capitalization AstraZeneca Corp.|AZN - Company Long-Term Debts|Company Short-Term Debt AstraZeneca|Quick Liquidity Indicator astrazeneca.com
- financial results and valuation multiples details:
AZN - Profit After Payment of Taxes|Expected Profit AstraZeneca PLC|AZN - Company Value to Net Income|Forward P/E Multiple AstraZeneca PLC|AZN - PEG Multiple|Enterprise Value to EBITDA Ratio AstraZeneca Corp.|AZN - Profit before deduction of interest, taxes, depreciation and amortization|Net earnings per share (EPS TTM) AstraZeneca|AZN - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months astrazeneca.com|AZN - Earnings per share growth this year|Earnings growth forecast for next year AstraZeneca PLC
Basic company analysis:AstraZeneca AB AZN
Original product of astrazeneca.com

AstraZeneca PLC (AZN) integration with academic centers and laboratories requires significant capital expenditures for drug development. Analyzing the company's EV/EBITDA chart, an investor compares the total enterprise value, including debt, against its operating efficiency. This multiple neutralizes the impact of taxes and depreciation, revealing the real value of assets. A stable range of values confirms the fundamental resilience of the business within a capital-intensive sector.

Competitors of AstraZeneca PLC

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Eli Lilly & Co. LLY|AbbVie Corp. (ABBV) - Company Value to EBITDA|NVS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MRK: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|NVO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation AMGN|PFE (Pfizer Corporation) - EV/EBITDA Multiple|Sanofi Group (SNY) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bristol-Myers Squibb (BMY)|gsk.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple TAK (Takeda)|Enterprise Value to EBITDA Multiple Teva Pharma|Dr. Reddy's Lab - EV/EBITDA Multiple|VTRS - EV/EBITDA Multiple|Roivant Sciences Ltd. (ROIV) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ZLAB - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio BHC|COSM (Cosmos Health, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio